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Abstract
Background: The prediction of the genetic disease risk of an individual is a powerful public health tool. While predicting risk
has been successful in diseases which follow simple Mendelian inheritance, it has proven challenging in complex diseases
for which a large number of loci contribute to the genetic variance. The large numbers of single nucleotide polymorphisms
now available provide new opportunities for predicting genetic risk of complex diseases with high accuracy.
Methodology/Principal Findings: We have derived simple deterministic formulae to predict the accuracy of predicted
genetic risk from population or case control studies using a genome-wide approach and assuming a dichotomous disease
phenotype with an underlying continuous liability. We show that the prediction equations are special cases of the more
general problem of predicting the accuracy of estimates of genetic values of a continuous phenotype. Our predictive
equations are responsive to all parameters that affect accuracy and they are independent of allele frequency and effect
distributions. Deterministic prediction errors when tested by simulation were generally small. The common link among the
expressions for accuracy is that they are best summarized as the product of the ratio of number of phenotypic records per
number of risk loci and the observed heritability.
Conclusions/Significance: This study advances the understanding of the relative power of case control and population
studies of disease. The predictions represent an upper bound of accuracy which may be achievable with improved effect
estimation methods. The formulae derived will help researchers determine an appropriate sample size to attain a certain
accuracy when predicting genetic risk.
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Introduction
Geneticriskof disease isan important component ofoverallriskof
disease in addition to environmental, socio-economic, and behav-
ioral risk factors. Therefore, predicting the genetic risk of disease for
an individual is a powerful tool in taking preventative measures
against the onset of the disease. Suchpredictions from genetic testing
are relatively straightforward when a disease is caused by one or few
genes. However, when a disease is of complex inheritance, the
genetic risk of the disease may be associated with many loci, each
explaining only a small portion of the genetic variance [1,2]. In this
case,the predictionof geneticriskofdiseaseofa particularindividual
becomes more challenging. Currently, prediction of risk for complex
diseases is based mainly on pedigree analysis but this approach yields
predictions of risk that are of low precision; for example predictions
would be identical for full siblings without offspring, yet the genetic
variation among them accounts for half or more of the genetic
variance [3,4].
The identification of very large numbers of single nucleotide
polymorphisms (SNP) has enabled the use of genome-wide
association studies (GWA) to detect alleles that are associated with
risk for complex diseases [5], such as Type II Diabetes and Crohn’s
disease [6]. In tandem with this substantive increase of SNP data,
several methods for quantifying and/or predicting genetic risk of
disease from multiple genes have been put forward [7,8]. Wray et
al.[9] extended these methods by using an GWA approach to
estimate the individual genetic risk of disease. Unlike the risk
estimates obtained using only pedigree, the estimates resulting from
such a GWA approach are more precise by allowing for
differentiation among full-siblings. In addition, no pedigree or
family history is needed either for estimating risk in one genotyped
sample from the population or for predicting risk in a fresh sample.
Similargenome-widemethodologyhasbeenproposed inanimaland
plant breeding to estimate additive genetic values for quantitative
traits [10,11]. One critical difference between the two genome-wide
approaches is that Wray et al. [9] set a significance threshold for the
lociselectedfordisease prediction,whereasMeuwissenetal.[10]use
all loci regardless of whether they affect or not the trait considered.
The approach of Meuwissen et al. [10] therefore attempts to achieve
the maximum estimate precision of the complete genetic value for a
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3395given dataset by including loci that may have too small of an effectto
achieve statistical significance, and, thus, reduces the overestimation
of allele effects [12].
Wray et al. [9] computed the precision of the individual genetic
risk estimates by simulation. While simulation studies are useful in
getting initial results on the number of phenotypic records needed to
achieve a desired level of accuracy, they are computer intensive and
time consuming with large numbers of markers. Most importantly,
they do not provide a deep insight on how all variables that affect
accuracy interact. Therefore, it is desirable to develop deterministic
equations that are responsive to all variables that influence accuracy.
Here we present simple expressions for the genome-wide
accuracy of prediction of genetic disease risk. We derive general
expressions for continuous traits and the necessary extensions for
dichotomous disease traits with data obtained either from
population studies or case control studies. The predictions are
tested by computer simulation under a variety of parameters
influencing accuracy, such as, for example, disease prevalence,
heritability and distributions of allele effects and frequencies
Materials and Methods
Derivation of Equations
The predicted accuracy that is derived below represents the
upper bound that can be achieved when estimating effects in one
population sample and then predicting individual genetic risk in
another sample from the same population. Throughout this article
the accuracy of predicted genetic risk (rgg ˆ) is defined as the
correlation between true and predicted genetic values. One
advantage of using rgg ˆ is that the factors influencing it can be
clearly derived using the principles of population genetics, as we
show below. We will first derive equations that are predictive of rgg ˆ
for a genome-wide approach with a continuous phenotype, such as
height, assuming a population study where individuals are sampled
at random. These will then be adapted to predict disease risk for a
dichotomous phenotype (‘affected’ or ‘unaffected’) with an
underlying continuous liability. The equations are then further
adapted to the situation of case control data.
Continuous phenotype
We will assume that there are nG potential loci affecting a trait
which are independent, biallelic and acting additively, where nG may
be large. These loci may be candidate genes or genetic markers of
which a significant proportion may have zero effects. For locus j,
j=1…nG, let a randomly chosen reference allele for that locus have
frequency pj and true allelic substitution effect bj.W es h a l la s s u m e
without loss of generality that the distribution of allele frequencies pj
is symmetric about p=K, and likewise that allelic effects bj are
symmetric about b=0. No further distributional assumptions will be
madehereonpjand bj,soforexample,manyoftheallelesegregating
may have negligible or zero effect. No assumptions are made
concerning the covariance between pj and bj in the populations
sampled. We intend to derive the accuracy of the prediction of the
additive genetic value (rgg ˆ) of an individual that can be achieved after
the measurement of nP phenotypes.
An estimate of the effect of each allele may be obtained by
regression of the phenotypic records on the genotypes one locus at
a time because the loci are independently segregating. Assume the
population variance of the phenotypes is 1. The estimated allele
substitution effect will be ^ b bj with expectation E ^ b bj
hi
~bj, and is
obtained by regressing the phenotypes on the observed number of
reference alleles in the genotype, denoted xij for individual i and
locus j (i.e. xij=0, 1, or 2). The sampling variance of the allele
estimate is var ^ b bj{bj
  
~s2
e
 
Sxx,j where s2
e is the residual
variance after regression on xij and Sxx,j=nPvar(xij) is the adjusted
sums of squares for xij. Although not assumed here, when the
population is in Hardy-Weinberg equilibrium Sxx,j is given by 2nP
pj(12pj). For the present, we shall conservatively take s2
e~1, which
underestimates the accuracy of the prediction.
Our aim is to predict the accuracy of a new population sample, so
we apply the original estimates to a new sample of the same popu-
lation. Values referring to the second sample will be ‘dashed’, hence
individual i from the second sample has x0
ij alleles at locus j.T h e
additive genetic value of i is given by gi~
P
locij x0
ijbj with estimate
^ g gi~
P
locij x’ij^ b bj.Th e nr2
g^ g g~ cov gi,^ g gi ðÞ ½ 
2
.
var gi ðÞ var ^ g gi ðÞ ½  .Noting
that g ˆi can be re-written as
P
locij x’ij bjz ^ b bj{bj
   hi
with
cov bj,^ b bj{bj
  
~0, it is seen that cov(gi, g ˆi)=var(gi) and that
r2
g^ g g~var gi ðÞ =var ^ g gi ðÞ .Oftheseremainingterms,var gi ðÞ ~h2
o,where
h2
o is the observed heritability for the trait, assuming the phenotypic
variance is 1. Again using the decomposition ^ b bj~bjz ^ b bj{bj
  
,i t
can be shown that var ^ g gi ðÞ ~h2
oz
P
locij var x’ij
  
nP var xij
      {1,
following from (i) the independence of the loci and (ii) the sampling
variance of ^ b bj derived earlier. Finally var x’ij
  
~var xij
  
, since the
second sample comes from the same population, so
r2
g^ g g~h2
o h2
oznG=nP
   {1, and substituting l=nP/nG gives
rg^ g g~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
lh2
o
lh2
oz1
s
: ð1Þ
Therefore accuracy is seen to be a function of the product of the
observed heritability h2
o and the ratio of the number of phenotypes
recorded to the number of loci involved, l. A second order
correction to relax the assumption s2
e~1 is given in Appendix S1,
where it is shown to result in an upward correction to rgg ˆ of
fractional magnitude &1=2r4
g^ g gl
{1.
Dichotomous disease phenotype.
We shall now derive the accuracy of predicting individual
genetic risk to disease (rgg ˆ) in a random population sample by
considering disease prevalence in a liability model [9]. For a
disease with prevalence q, phenotypes are defined as si=0 for
unaffected, and si=1 for affected, so E[si]=q and var(si)=q(12q).
Individuals with the highest liability are affected by the disease. Let
liability be yi, scaled so E[yi]=0 and var(yi)=1, and bj is the
regression of liability on the number of reference alleles at locus j.
The linear predictor of si on yi is given by si=q+qiqyi [13], where iq
equals the mean liability of affected individuals, which we will term
the selection intensity [3] corresponding to the prevalence of the
disease in the population. Let the slope of the regression of si on xij
be ^ p pj, then E ^ p pj
  
~qiqbj, with sampling variance, estimated
conservatively using the phenotypic variance q(12q)
var ^ p pj
  
~q 1{q ðÞ nP var xij
      {1: ð2Þ
The coefficients ^ p pj may be rescaled to give estimates
^ b bj~^ p pj
 
qiq
  
, with sampling variance
var ^ b bj
  
~ 1{q ðÞ nP var xij
  
qi 2
q
hi {1
: ð3Þ
Repeating the argument outlined above for a continuous pheno-
type with var gi ðÞ ~cov gi,^ g gi ðÞ ~h2
l , and var ^ g gi ðÞ ~h2
l z nGq 1{q ðÞ ½
var x’ij
  
 : 1{q ðÞ
 
nPvar xij
  
qi2
q
hi {1
, where h2
l is the heritability
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r2
g^ g g~
nPh2
l qi 2
q
nPh2
l qi 2
qznG 1{q ðÞ
ð4Þ
Robertson and Lerner [14] show that the relationship between
additive heritability on the observed scale and the heritability on
the liability scale satisfies
h2
o&h2
l q2i2
q q 1{q ðÞ ½ 
{1: ð5Þ
Substitution then results in Equation (1) with h2
l being replaced by
h2
o:
rg^ g g~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
lh2
o
lh2
oz1
s
: ð6Þ
Therefore the dichotomous phenotype study of disease results in
an identical formula for rgg ˆ as the continuous phenotype provided
the heritability used is that for the observed dichotomous scale.
Case Control Disease Study
The formulae will now be extended to derive the accuracy rgg ˆ of a
genetic risk prediction when applying a case control design to a
dichotomous phenotype. The need for modification of the equations
for a casecontrol design comes fromthe selection ofindividualsfrom
within the population to achieve a prevalence within the sample of
cases and controls of w, and where typically w=1/2 with equal
numbers of cases and controls. Parameter values post-selection will
be ‘starred’. It is assumed in the following without loss of generality
that cases are less common than controls in the population so
q#w#1/2. Two parameters in particular need to be re-estimated
because of the selection practiced: (i) S
1
xx,j=nP var xij
  
; and (ii) the
regression of si on xij, E ^ p p
1
j
hi
=qiqbj. Both these corrections can be
made as shown in detail in Appendix S2.
Briefly, assuming no covariance between pj and bj,
E var xij
     
~var gi ðÞ
.
nG E b
2
j
hi   
. S
1
xx,j is nPvar*(xij) and so since
nG and E b
2
j
hi
over loci are unaffected by the sampling of cases and
controls, E[var*(xij)]=E[var(xij)]var*(gi)/var(gi). Appendix S2 shows
that using Normal theory var1 gi ðÞ ~var gi ðÞ 1{h2
l i i{x
     
.
Further E ^ p p
1
j
hi
~wi q{i
  
bj 1{h2
l i i{x
      {1, where x is the
truncation point of a Normal distribution for upper-tail probability
q, i ¯=wiq2(12w)i(12q).
Approximating s2
e~0:25 for a binomial trait with probability
K, appropriate for equal numbers of cases and controls, gives
var ^ b bj
  
~ 1{w ðÞ 1{h2
l i i{x
     
wn P var xij
  
iq{i
   2    hi {1
,
and substituting l results in
r2
g^ g g~
lwh2
l iq{i
   2
lwh2
l iq{i
   2z 1{w ðÞ 1{h2
l i i{x
      : ð7Þ
Changing the heritability from the liability scale for a population
sample to the observed scale for a population sample using
Equation (5) produces
r2
g^ g g~
lh2
o
lh2
ozq 1{q ðÞ 1{h2
l i i{x
     
w{1 1{w ðÞ
{1 : ð8Þ
Finally, substituting q 1{q ðÞ 1{h2
l i i{x
     
w{1 1{w ðÞ
{1~c,
gives
r2
g^ g g~
lh2
o
lh2
ozc
: ð9Þ
Thus the form of rgg ˆ for a case control study shows equivalence to the
rgg ˆ of continuous and dichotomous phenotypes provided heritability
isontheobserved scaleand the appropriate changes are made in c to
account for the selection of cases and controls. The value of c is 1 in
population studies (Equation (6)), where w=q (and, hence, i ¯=0).
When q,w,1/2, c,1 and there is an increase in rgg ˆ compared to a
population study with the same l.
Simulations
Stochastic computer simulations were used to test the determin-
istic predictions of rgg ˆ for a number of parameters affecting the
continuous and dichotomous phenotypes. We describe the full
simulation method for the continuous trait and then state additional
steps that were needed for the dichotomous phenotypes (random
population sample and case control). In all scenarios (i) individuals
were unrelated; (ii) loci were independent; (iii) all genetic action was
additive; (iv) for simplicity, loci were assumed to be in Hardy-
Weinberg equilibrium; and (v) each scenario was replicated 100
times, except for case control scenarios with l=0.02 where 500
replicates were run. Furthermore for initial simulations (vi) allele
frequenciesweresampledfroma uniformdistributioncorresponding
toacommon-disease-common-varianthypothesis(CDCV)[15];and
(vii) allele effects were drawn from a reflected exponential
distribution which was made symmetric about x=0. Items (vi) and
(vii) were modified as described below.
For the continuous phenotypes, the phenotypic variance was 1.
True additive genetic values for nP individuals were calculated as
(12pj)bj and 2pjbj for the minor and major alleles, respectively, for
each of nG simulated loci, and summing over loci. The value of nG
used in most scenarios was 1000 and nP varied accordingly,
depending on l. Two exceptions were l=0.02, where
nG=20,000, and the scenarios in which l was kept constant with
nG=100. The scale factor of the exponential distribution was
chosen to obtain the required additive heritability h2
o
  
. Pheno-
typic records were simulated by adding independent environmen-
tal terms to the true genetic effects drawn from a Normal
distribution with mean zero and variance 1{h2
o. Allele substitu-
tion effects ^ b bj
  
were estimated by regression of nP phenotypic
records on genotypes one locus at a time. A second sample of
individuals was then simulated with genotypes based on the same
allele frequencies and effects as the original population. The
estimated additive genetic values were then computed according
to the following model: ^ g gi~
P
loci,j x’ij^ b bj, as described above.
Finally, rgg ˆ was calculated as the correlation between true and
estimated additive genetic values. Bias was also assessed by the
slope of the regression of gi on g ˆi.
The continuous phenotype case was tested for robustness to
different distributions of allele frequency and effects, and their
correlation. The allele frequencies were also drawn from a beta
(U-shape) distribution, consistent with a neutral allele model [16],
with parameters alpha=0.3, and theta=0.3. Allele effects were
also sampled from a normal distribution with mean zero. The
effect of having a percentage of loci with zero effects was
investigated by setting a proportion of the effects to zero while
keeping the overall genetic variance constant. In all cases, the scale
factor for the distribution of allele effects was modified to maintain
the desired h2
o.
Genetic Disease Risk Accuracy
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correlation between the heterozygosity at a locus and the squared
magnitude of the allele substitution effect at a locus. This was done
for a uniform distribution of allele frequencies and the reflected
exponential distribution of allele effects. This was achieved
empirically: if the randomly drawn frequency had heterozygosity
greater than the median (i.e. 2p(12p).0.375) then the magnitude
of the allele effect was drawn to be less than the median of the
distribution of the magnitudes.
The simulation of a random population sample for the
dichotomous disease phenotype followed the same structure as
above but contained the additional step of treating the underlying
continuous phenotype distribution as a liability for the disease with
heritability h2
l on the liability scale [14]. Therefore, with
prevalence q, the fraction q of the population with the greatest
liability were considered to be affected. Therefore allele effects
were estimated from the dichotomous phenotype and the
accuracy, rgg ˆ, was calculated as the correlation between the true
and estimated genetic liability for the disease estimated in an
independent population sample.
Case control studies were simulated with an equal number of
cases and controls (i.e. w=1/2). A dichotomous disease phenotype
with sample size nP was simulated by including an additional
selection step which expanded the population size to nP[2qd]
21.
The liabilities were constructed as for the population study of a
dichotomous disease, the nP/2 individuals with the greatest
phenotypic liability were considered to be affected cases, and a
further nP/2 were randomly chosen from those remaining as
control phenotypes. Allele effects were estimated as for the
population studies, and the accuracy was estimated from a
randomly-drawn independent population sample of size nP.
Results
Population-wide studies of continuous phenotypes
When allele effects were drawn from an exponential distribution
andfrequencieswerefromtheuniform,thedeterministicformulafor
rgg ˆ was found to predict the simulated data reliably across the wide
range of parameters used (Table 1). The prediction errors across all
parameters studied were in the range of 21.3 to 4.0% (Table 1).
The close agreement between the predicted and achieved
accuracies is also seen in Table 2 and was maintained when: (i)
allele frequencies were drawn from a beta-distribution (% error
20.9 to 0.7); (ii) allele effects were drawn from a normal
distribution (% error 20.8 to 5.0); (iii) exponential allele effects
were mixed with varying proportions of alleles with no effects,
ranging from 0 to 95% (% error 0.1 to 26.6, Table 3); (iv) l’s
ranging from 0.02 to 5 were investigated (% error 220.0 to 4.0,
Table 1); and (v) the genetic architecture was varied by keeping l
constant and changing nG (nG=100, % error 0.1 to 7.6; and
nG=1000, % error 20.5 to 0.0). It should be noted that the large
percentage errors seen when l=0.02 are due to low rgg ˆ, where the
absolute difference between the expected and simulated rgg ˆ was still
less than 0.02. The introduced correlation between heterozygosity
and squared substitution effect was tested with l=1 and nG=1000
using the empirical procedure described in the Materials and
Methods. With an achieved correlation of 20.36 and an observed
h2
o~0:39, the predicted accuracy from Equation (1) was 0.53, with
an error of 1.1% when compared to simulation. In conclusion, it is
clear that the deterministic rgg ˆ is robust to wide distributional
assumptions on the joint distribution of frequency and effect of
allele substitution, as predicted from the derivation.
Therefore the predictions of genome-wide accuracy shown in
Figure1 based on Equation (1)fordifferent values of observed h
2 and
l have wide applicability. For all l, the accuracy was most sensitive
to h
2 when h
2 was low and this sensitivity was potentiated by higher
numbers of phenotypes per genotype tested. The accuracies are
functions of lh
2, so the required l to achieve a given accuracy is
proportionalto 1/h
2. Thus,the numbersofphenotypes per genotype
needto betwiceashigh forhalf theheritability.Toobtainaccuracies
of 0.71, corresponding to predicting half the genetic variance, l=1/
h
2, and therefore l must be $1b e c a u s eh
2#1.
Population-wide studies on dichotomous disease
phenotypes
The form of the predicted accuracy (rgg ˆ) is very similar to that for
a quantitative trait. Again the prediction of rgg ˆ was very good (%
error 214.1 to 1.6; see Table 1). The validity of the prediction
resulting from Equation (6) was robust to varying disease
Table 1. Predicted accuracy and percentage prediction error
assessed by simulation with disease prevalence=0.1 (SE
range 0.0004–0.0065).
h
2b l
a=0.02 l=0.50 l=1.00 l=5.00
P
c %error
d P %error P %error P %error
C
e 0.1 0.045 4.0 0.218 3.6 0.301 2.2 0.577 0.4
0.5 0.100 2.1 0.447 20.5 0.577 20.2 0.845 20.1
0.9 0.133 21.3 0.557 0.2 0.688 20.2 0.905 20.1
DP
f 0.1 0.026 214.1 0.130 26.6 0.182 22.2 0.382 21.6
0.5 0.058 21.1 0.281 0.6 0.382 21.1 0.679 0.2
0.9 0.078 29.8 0.365 1.6 0.485 0.8 0.779 0.2
DC
g 0.1 0.043 20.6 0.209 2.4 0.290 3.5 0.560 21.9
0.5 0.089 24.3 0.407 3.0 0.533 0.8 0.816 22.9
0.9 0.112 220.0 0.490 20.4 0.622 20.4 0.872 23.3
al=number of phenotypes per number of loci.
bh
2=heritability (observed scale for C and DP, liability scale for DC).
cP=predicted accuracy of estimated additive genetic value.
d% error=percentage prediction error=100(P2accuracy from simulation)/P.
eC=continuous phenotype.
fDP=dichotomous phenotype, population study.
gDC=dichotomous phenotype, case control study.
doi:10.1371/journal.pone.0003395.t001
Table 2. The effects of different distributions of allele
frequency and effects on accuracy in a continuous phenotype
with observed heritability=0.5 (SE range 0.0004–0.0057).
l
a Predicted Simulated
Beta
b/Nrm
c Beta/Exp
d Uni
f/Nrm Uni/Exp
0.02 0.100 0.095 0.093 0.100 0.097
0.50 0.447 0.442 0.436 0.451 0.450
1.00 0.577 0.577 0.579 0.576 0.578
2.00 0.707 0.709 0.714 0.704 0.709
5.00 0.845 0.849 0.848 0.846 0.846
10.00 0.913 0.914 0.914 0.913 0.912
al=number of phenotypes per number of loci.
bBeta=beta distribution (alpha=0.3, theta=0.3) of allele frequencies.
cNrm=normal distribution of allele effects.
dExp=exponential distribution of allele effects.
fUni=uniform distribution of allele frequencies.
doi:10.1371/journal.pone.0003395.t002
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Table 4). The form of the prediction in Equation (6) is a function
of l and the observed additive heritability on a (0,1) scale, but this
can be achieved with varied combinations of disease prevalence
and underlying heritability of liability. This is shown in Table 5,
which also demonstrates that, as predicted from Equation (6), rgg ˆ is
a function of only h2
o as accuracy remains constant with varied
disease prevalence and h2
l .
The predicted rgg ˆ of population studies of continuous phenotypes
and dichotomous disease phenotypes with an underlying contin-
uous liability follow the same functional form as seen in
Equation (6). Therefore, Figure 1 can be used to derive predicted
rgg ˆ for dichotomous phenotypes as well as continuous phenotypes.
However, note that in the liability model, even if liability was fully
determined genetically, the additive heritability on the observed
scale will never exceed 0.64 (i.e. 4h(0)
2, where h(x) is the
standardized normal density function) with the remaining genetic
variation appearing non-additive. The corresponding maximum
rgg ˆ achievable will be reduced and this will be most serious for low
l. Even with the most favorable circumstances of q=1/2 and
liability h2
l ~1, the accuracy will never exceed 0.71 if l,1.56, and
it should be expected that l needs to be much greater than this to
explain half the genetic variance. This circumstance should not be
expected to change when using other disease models than the
liability, since the loss of rgg ˆ arises from the loss of quantitative
information when moving from a continuous genetic value
(however defined) to the categorical observation of affected or not.
Case control studies of dichotomous disease phenotypes
The prediction formula for accuracy of case control studies (rgg ˆ)
is not a simple function of l and the observed h2
o, but also depends
on both the heritability on the liability scale and the disease
prevalence, as seen from Equation (8). Therefore, comparisons
require consideration of how c in Equation (9) varies. The
simulations assumed w=1/2, with equal numbers of cases and
controls. Although, as seen in Table 1, the predictions are
generally good (% error 220.0 to 3.5), where the large error
Table 3. Accuracy for continuous phenotype when setting
0.95 of nG
a loci to zero (l=0.02=400nP
b/20,000nG, SE range
0.0042–0.0057).
h2
o
c 0.95 of nG zero 0.0 of nG zero Predicted
0.1 0.057 0.043 0.045
0.5 0.101 0.097 0.100
0.9 0.129 0.135 0.133
anG=number of loci.
bnP=number of phenotypes.
ch2
o =observed heritability.
doi:10.1371/journal.pone.0003395.t003
Figure 1. Predicted accuracy of estimated genetic values of a continuous phenotype. Predicted accuracy of estimated additive genetic
values of a continuous phenotype as a function of observed heritability and number of phenotypes per genotype tested, l=0.02, 0.1, 0.5, 1, 2, 5, 10
and 20 from minimum to maximum accuracy respectively.
doi:10.1371/journal.pone.0003395.g001
Table 4. Accuracy for a dichotomous disease trait as
prevalence varies (
ah2
l ,
bl=1, SE range 0.0026–0.0048).
Prevalence Study Type DP
c Study Type DC
d
P
e % Error
f P % Error
0.01 0.186 20.8 0.593 211.1
0.03 0.271 21.9 0.568 26.8
0.05 0.317 0.3 0.554 23.5
0.10 0.382 20.6 0.533 0.6
0.20 0.444 1.4 0.511 22.5
0.30 0.473 1.2 0.499 20.2
0.40 0.487 20.6 0.493 1.2
0.50 0.491 0.0 0.491 1.4
ah2
l =heritability on liability scale.
bl=number of phenotypes per number of loci.
cDP=population study of dichotomous phenotypes.
dDC=case control study of dichotomous phenotypes.
eP=predicted accuracy of additive genetic values.
f% error=percentage prediction error=100(P2accuracy from simulation)/P.
doi:10.1371/journal.pone.0003395.t004
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underestimation of rgg ˆ as prevalence becomes low (Table 4).
The value of rgg ˆ for case control studies is best illustrated by
comparison with population studies of dichotomous disease traits.
Figure 2 integrates this information and shows the relationship of
prevalence and observed heritability in population and case
control studies. Values of rgg ˆ below the narrowly dashed line
derived from Equation (5) are not possible under the liability
model, for example, an observed additive heritability of 0.5 and a
prevalence of 0.1 could not exist in the same dataset. Each contour
represents an level of constant rgg ˆ, where the dashed lines represent
a population study and the solid lines denote a case control design
with w=1/2. As described above the contours are vertical for
population studies as, given h2
o, the accuracy is independent of q,
but for case control studies move towards lower h2
o as prevalence
decreases. Several clear conclusions on case control studies can be
drawn: (i) the overall trend of rgg ˆ increasing with more phenotypes
per number of genotype holds true for case control studies
(Table 1); (ii) population studies and case control studies are
equivalent when the prevalence is 0.5 (Figure 2); (iii) a case control
study is always more accurate than a population study with the
same number of individuals genotyped (Figure 2); (iv) for a
constant h2
l , rgg ˆ increases as the disease prevalence increases in
population studies, since this increases h2
o, but in case control
studies rgg ˆ increases as the disease prevalence decreases because of
the more intense selection induced by the less prevalent disease
(Table 4).
Discussion
We have derived simple deterministic predictions of rgg ˆ in
continuous and dichotomous phenotypes using either a population
or a case control study and we have shown them to be
appropriately responsive to changes in disease prevalence,
heritability, and the number of phenotypic records per number
of risk loci to be estimated. In addition, the equations have proven
robust to changes in allele effect distributions, including different
fractions of loci with zero effect and differing allele frequency
Table 5. Simulated accuracy of a population study for a
dichotomous phenotype as prevalence and h2
l
a varies and h2
o
b
stays constant (l
c=10, h2
o~0:2, predicted accuracy=0.816,
Equation (4), SE range 0.0025–0.0038).
Prevalence h2
l Accuracy
0.05 0.893 0.810
0.10 0.584 0.814
0.20 0.408 0.814
0.30 0.347 0.813
0.40 0.322 0.813
0.50 0.314 0.813
ah2
l =heritability on liability scale.
bh2
o =heritability on observed scale.
cl=number of phenotypes per number of loci.
doi:10.1371/journal.pone.0003395.t005
Figure 2. Predicted accuracy of estimated genetic risk from population and case control designs of a dichotomous phenotype.
Contour plot of predicted accuracy for varied prevalence and additive heritability on the observed scale, in population studies (dashed vertical line)
and case control studies (solid line) of dichotomous phenotypes. Each contour represents a line of constant accuracy, starting from the right 0.9, 0.8,
0.7, and 0.6. The narrowly dashed line is derived from Equation (5) with h2
l ~1, so values below this line are not possible under the liability model.
doi:10.1371/journal.pone.0003395.g002
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between the magnitude of allele effects and heterozygosity,
although, in principle, this robustness does not hold for case
control studies. This advance in understanding has been used to
summarize the influence of critical parameters such as heritability
and numbers of phenotypes and risk loci on accuracy of
prediction, and also to show the degree to which case control
designs can add power to studies.
The approach taken here has been to assume the potential loci
affecting the trait are known, and this has an impact that is double
edged. First, it allows for a clear quantification of the limitations
imposed on rgg ˆ by the number of phenotypes obtained, irrespective
of marker densities. The information gained by doing so is of equal
importance to knowing the number of markers needed for a
certain rgg ˆ but seems to have received less attention recently.
Second, it implies that the predicted rgg ˆ are upper bounds for the
data obtained, since some loss of rgg ˆ will occur through the use of
markers which are potentially in imperfect linkage disequilibrium
(LD) with loci with effect [17], and the inclusion of candidate loci
that may have no effect within the population.
The impact of including these loci with no true effect may be
explained by two applications of our formulae. The first
application assumed the loci affecting a disease trait are known
and thus rgg ˆ demonstrates an upper bound on the accuracy; for
example, consider nG=1000 loci with effects greater than 0,
nP=10,000 phenotypes and h2
o~0:1, then the predicted accuracy
is obtained with l=10, and will be 0.71. Now consider if those
1000 loci are contained with a set of nG=100,000 marker loci,
with 99% having zero effect so that now the accuracy is obtained
with l=0.1; our predictive equations remain valid and predict an
accuracy of 0.10. From these applications of our formulae it is
clear that the approach of estimating loci effects one at a time will
inevitably result in low accuracies, and further, adding more
marker loci with zero effects while using the same approach will
reduce the expected accuracy. The low accuracies predicted
accord with the empirical findings from large scale studies of
human data that have recently been reported [18]. It is clear that
alternative approaches to prediction will be needed to bridge the
gap and raise accuracies towards the potential placed by the
phenotype collection.
Nevertheless, potential alternative approaches are available and
evidence already exists that these approaches may significantly
increase predictive accuracy. One approach is to implement model
selection approaches. Similarly, improvements in rgg ˆ can be
achieved by implementing model selection least squares proce-
dures to identify a subset of SNP from which to predict effects
[10,19], or by using more complex procedures to identify a subset
to set to zero [20]. Some of these studies [10,19,20] also
incorporate the use of prior information within Bayesian
procedures and demonstrate significant increases in accuracy over
least squares. Increasing the number of markers when using priors
can increase accuracy because the size of the marker subset chosen
stays the same due to the prior but the portion of the genetic
variance captured by the markers subset increases [21]. However
the use of Bayesian approaches will demand reliable distributions
for incorporation into models. Literature estimates informing
priors on nG and the distributions of the effects will become more
widely available as GWA studies become more powerful [1,22].
Full genome-wide methods [10,11], where genetic risk or additive
genetic values are estimated in one step, using all loci
simultaneously particularly if they are correlated, might be
expected to approach the upper bound of rgg ˆ faster than methods
which impose significance thresholds and, thus, do not capture all
the genetic variation. From the results presented here it may be
argued that priors on the numbers of loci positively contributing to
the genetic variance will be more critical than those describing the
distribution of gene effects.
In this paper we have used a liability model for disease instead
of the commonly used log genetic risk model and the impact of
doing so is likely to be small for large datasets. For a set of h2
o and q,
an underlying log-risk can be approximated well by a liability
[9,23] and the distribution of effects on the log-risk scale will be
transformed to a distribution on the liability scale, and the
predictions developed here are not dependent on the distribution
of effects. However there is evidence that distinctions may be
larger when q is very close to zero or one [24].
A critical assumption of the genetic models studied was that the
loci acted independently. In humans, most LD stretches for 10 to
30 kb, while some linkage disequilibrium blocks may be .100 kb
[25]. The human genome contains 3.1 billion bases [26] and,
assuming 2000 known loci contribute to the additive genetic
variance, each genomic segment between them would be 1550 kb.
This confirms that this model is viable in human. One could apply
our formulae by interpreting nG as the number of independent
chromosome segments (i.e. haplotype blocks). The length and,
thus, the number of these segments would depend on the amount
of LD present in the genome. The number of such segments have
been estimated directly from pair-wise LD between markers [27]
and closely related measures, such as the number of independent
tests on the genome, have been estimated using principle
component analysis [28] and have been derived analytically for
specific experimental designs [29]. When LD exists, either
between markers and risk loci or between risk loci, the predictive
efficiency of our equations will be reduced. Modeling the pattern
of LD by extension of our formulae would thus be important when
many loci are used, as with dense SNP marker maps, or when
predicting additive genetic values in other species, such as some
livestock populations where the extent of LD is large compared to
human [30,31].
An attraction of molecular predictors of genetic risk compared
to pedigree predictors is the potential to apply the predictions
more widely within populations and across populations. Obtaining
sufficient accuracy within populations can be achieved by the
quality and size of sampling, but there are additional factors in
play when transfer across populations is being considered. For
example, one benefit of genome-wide prediction is that individual
allele effects are estimated with a precision that is related to the
molecular variation observed at the locus, var(xij), which deter-
mines the contribution of genetic variance when combined with
the squared magnitude of effect. This benefit may break down
when predictions are transferred across populations. As an
illustration, consider a rare allele of large effect which will be
relatively imprecisely estimated in the estimation sample, but
because the contribution of the locus to total variance is small
there is only a small impact upon the accuracy of further
predictions within the same population. In a different population,
such an allele may have a greater frequency and contribute a
greater part of the genetic variance, and, consequently, the
predictive accuracy will suffer. Specifically, the ability to transfer
predictions will depend on var(xij) in each of the two populations
used for estimation and application, and this in turn depends on
both the allele frequency (pj) and the degree of admixture present
in the population. Furthermore, an additional risk of transferabil-
ity across populations is the presence of epistasis which may
differentially influence bj.
Any directional selection present in the population is likely to
introduce a covariance between the magnitude of allelic effect and
heterozygosity, since selection promotes the movement of alleles of
Genetic Disease Risk Accuracy
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create large genetic variance, towards extreme frequencies. The
predictions of rgg ˆ developed make no assumption of the covariance,
and hence are robust to such selection in the population prior to
estimation in population studies. In contrast, the derivation for the
case control study does assume independence of heterozygosity
and magnitude (as described in Appendix S2). However, in the
limited simulations carried out with such covariances in case
control studies, the impact of the breaking this assumption
appeared small (results not shown).
Our derivations show that rgg ˆ can be reduced to very similar
forms for population and case-control studies of continuous and
dichotomous phenotypes (c.f. Equations (1), (6) and (9)). The
common element affecting rgg ˆ for all three equations is the term
lh2
o, describing the joint effect of l, the number of phenotypic
records per locus associated with the trait, and the observed
heritability. Increasing either of these improves rgg ˆ, but the study
shows that the major determinant of the trade-off between these
two factors is their product. For a population study lh2
o is
completely sufficient to determine accuracy, independent of
prevalence (q) and heritability h2
l
  
of liability for a dichotomous
trait, but for a case control study both q and h2
l retain some
influence on rgg ˆ over and above their impact upon h2
o. This is
because, in a case control study, the term c in Equation (9) is
adjusting for the selection of the cases and controls, and the
strength of selection will depend upon q, and its impact on genetic
variance will depend on h2
l .
The predictive equations are a good fit to the simulated values
and we have demonstrated, by theory and simulation, that they
are independent of allele frequency and effect distributions. The
formulae have increased the understanding of the relative
differences between predicting rgg ˆ in a random sample of a
population and in case control studies. The expressions for rgg ˆ
derived will help researchers design experiments of appropriate
size to estimate genetic risk to disease.
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